Proteome Sciences Bets on Services Growth and New Tags After TMT Slump

Proteome Sciences ( (GB:PRM) ) has provided an update.

Proteome Sciences reported a sharp decline in 2025 group revenue to £3.76m from £4.89m, as TMT reagent sales and royalties nearly halved due to deep U.S. National Institutes of Health funding cuts, though proteomic services revenue more than doubled to £2.06m and losses narrowed slightly. Management described 2025 as the trough of the cycle, highlighting strong order momentum in its San Diego facility, substantial GCLP contracts extending into 2027, and a January 2026 equity raise of £972,000 to fund capacity expansion and the launch of new chemoproteomics workflows and advanced 96-plex and DXT tagging products, while also announcing the planned departure of long-serving non-executive director Roger McDowell at the upcoming AGM.

The company is pinning future growth on a recovery in TMT demand as U.S. research budgets stabilise, alongside new licensing and manufacturing revenues from its 96-plex TMT pro extension and DXT isotopic DIA tags, which are expected to open high-throughput markets not covered by its existing Thermo Scientific agreements. Executives say the shift in revenue mix toward higher-growth services, combined with expanded U.S. presence and an enriched product pipeline, should improve the group’s long-term revenue profile and strengthen its positioning within the proteomics tools and services segment despite ongoing adjusted EBITDA losses and modest year-end cash levels.

Spark’s Take on PRM Stock

According to Spark, TipRanks’ AI Analyst, PRM is a Neutral.

The score is held down primarily by very weak financial performance (declining revenue, ongoing losses, negative cash flow, and negative equity). Technicals are also bearish with the stock below key moving averages, though oversold signals modestly offset the downside. Valuation is unfavorable due to a negative P/E and no dividend support.

To see Spark’s full report on PRM stock, click here.

More about Proteome Sciences

Proteome Sciences plc is a specialist contract research provider focused on proteomics, offering mass spectrometry-based services to support drug discovery, development and biomarker identification for pharma and biotech clients. The company also develops and licenses proprietary isobaric tagging reagents such as TMT and emerging DXT tags, targeting high-throughput protein analysis and multiplexed workflows across global life sciences markets.

Average Trading Volume: 376,151

Technical Sentiment Signal: Sell

Current Market Cap: £5.52M

For a thorough assessment of PRM stock, go to TipRanks’ Stock Analysis page.